Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

U.S. Biotechnologist Robert Langer Named European Inventor Award 2016 Finalist
  • USA - English


News provided by

European Patent Office

Apr 26, 2016, 10:15 ET

Share this article

Share toX

Share this article

Share toX

Robert Langer
Robert Langer

CAMBRIDGE, Mass. (PRWEB) April 26, 2016 -- The European Patent Office (EPO) today announced that M.I.T. Professor Robert Langer has been named as one of three finalists for the European Inventor Award 2016 in the category “Non-European countries.” The winners of the 11th edition of the EPO’s annual innovation prize will be announced at a ceremony in Lisbon on June 9th.

Robert Langer's invention unlocks a new generation of medical treatments as a powerful weapon against cancer.

Post this

A new generation of anti-cancer drugs “starves” tumors by interrupting their connection to the body’s blood supply. But as a downside, these so-called angiogenesis inhibitors lose efficacy while traveling the bloodstream before reaching tumors. A "smart" drug delivery method invented by American biotechnologist Robert Langer (67) solves the problem. It encapsulates cancer-starving drugs within “wafers” created out of biodegradable plastics. Implanted right at the tumor site, they dissolve for targeted release. And, cancer-fighting drugs are really just the beginning for the M.I.T. professor who is regarded as a pioneer in an emerging field of medical technologies. Langer's bioplastics can also be shaped into ingestible capsules, cardiovascular stents, and into "scaffolding" supporting the growth of new body tissue.

“Robert Langer's invention unlocks a new generation of medical treatments as a powerful weapon against cancer,” said EPO President Benoît Battistelli announcing the European Inventor Award 2016 finalists. “On the way to a medicine of the future, the concept of biodegradable plastics provides doctors with new and previously unthinkable approaches that are already changing treatment outcomes around the world.”

TARGETED TREATMENT FOR BRAIN CANCER
Thanks to Langer’s innovation, doctors now have a powerful weapon against an aggressive form of brain cancer known as glioblastoma multiforme (GBM). GBM is both particularly difficult to treat due its proximity to healthy tissue and relatively prevalent: it accounts for 52% of all primary brain tumors. Approved for clinical use in 1996, Langer's ingenious method allows GBM to be targeted at the tumor site, precisely delivering drugs in exact dosages without exposing healthy tissue to aggressive chemicals. The biologically tolerable polymers are now the building blocks for previously unthinkable treatment approaches, especially targeted drug delivery.

STARVING TUMORS AT THE SOURCE
The idea of starving tumors with angiogenesis inhibitors is not a new one. As early as 1971, Robert Langer and other physicians saw their potential for stunting tumor growth. But as tests soon revealed, the effectiveness of angiogenesis inhibitors declines radically when injected or ingested. Plus, in the case of brain tumors, transporting the drugs past the blood-brain barrier proved an additional challenge. In order to solve the problem, Langer and his team at the Massachusetts Institute of Technology envisioned a delivery vector that would transport the drugs right where they are needed: the site of the tumor.

After researching the emerging field of bioplastics, Langer zeroed in on so-called Poly(beta-amino ester)s, a family of biodegradable polymers that can be moulded via nanotechnology into a wafer-like form. During minimally invasive surgery, doctors implant the drug-laden wafer next to the tumor, where it is gradually broken down by the body's metabolism, thereby releasing its payload of cancer-starving drugs with maximum efficiency. This method not only avoids the blood-brain barrier altogether, but it also solves a second problem: the powerful cancer drugs can have neurotoxic effects – harming healthy brain tissue – if delivered in an untargeted manner.

A NEW ERA OF TARGETED MEDICINE
The innovation ushers in a new era of targeted therapies for ailments such as cancerous tumors and heart disease. Doctors can now integrate powerful drugs into moldable bioplastics wafers that dissolve at exactly the right location to release their payload. “You get high concentrations in the brain where you want them,” explains Langer. “And low concentrations in the rest of the body where it might cause harm.” During Langer's clinical trials, patients with GBM achieved a survival rate of 63%, compared with 19% in the control group. To date, over 20 million patients worldwide have been treated with angiogenesis-inhibiting substances, and therapies derived from Langer's bioplastics, including drug-coated cardiovascular stents, have benefited more than one million.

HEAD OF WORLD'S BIGGEST BIOMEDICAL ENGINEERING LAB
Robert Langer started his career with a BSc in Chemical Engineering at Cornell University in 1970, followed by his PhD in Chemical Engineering at MIT in 1974. Although his interest in bio-polymers started as a young researcher, Langer spent almost 28 years perfecting the implantable bioplastics technology after publishing his first findings – US FDA approval final came in 1996 – and he experimented with over 200 variations of polymers at M.I.T.'s Folkman laboratory in the first two years alone. Named the most-cited engineer in history by Science magazine, the prolific inventor has authored over 13,000 articles and contributed to 1,100 patents, with inventions licensed by 300 pharmaceutical companies. His publications have been cited over 194,000 times.

A constant advocate of bridging the gap between research and the marketplace, Langer leads the world's largest biomedical engineering lab – the David H. Koch Institute at M.I.T. – with over EUR 8.9 million (US $10 million) in annual grants and over 100 researchers. His inventions jumpstarted a new class of treatments for GBM, prostate cancers, endometriosis, and mental illnesses with considerable market success. The bioplastics-encapsulated drug Gliadel (GBM) generated sales of around EUR 32.5 million (US $35.8 million) in 2006, Zeneca Zoladex (prostate cancer) netted around EUR 905 million in 2013, and Risperdal Consta (schizophrenia) EUR 1.4 billion in 2014. Third-party analysts expect the GBM treatment market to grow from about EUR 273 million in 2013 to EUR 566 million by 2020.

ADDITIONAL RESOURCES:
YouTube video on Robert Langer
Additional video and photo material
Read more about the inventor
View the patents: EP1639029, EP2075015

FIGHTING CANCER WITH PATENTED TECHNOLOGIES
Robert Langer's bioplastic-coated drugs are part of a new wave of medical technologies that provide safe and efficient alternatives to radical surgery and aggressive chemotherapy. Nano capsules, proton radiation, ultrasound, antibodies, and more: Innovative concepts, protected by patents, are already benefitting patients worldwide.

Read more about new weapons against cancer.
About the European Inventor Award
About the European Patent Office (EPO)

Peter Gorman (USA), European Patent Office, http://www.epo.org, +1 617-669-4329, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.